Skip to content

Discontinued — last reported Q4 '19

D&A at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
$75.6M+8.6%
Quest Diagnostics logo
Quest DiagnosticsDGX
$37M-5.1%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%
CareDx logo
CareDxCDNA
$3.9M+8.3%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$4.82M-0.8%
Revvity logo
RevvityRVTY

Segments

By segment

See full
Reportable Segment$230K-10.9%

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-28.2%
Enterprise value$117.78M-22.1%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The official record: Exagen Inc.’s 10-K, filed March 25, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.